- Home
- GLMD vs XBIO Comparison
GLMD vs XBIO Comparison
Compare GLMD & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GLMD | XBIO |
|---|---|---|
| Founded | 2000 | N/A |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6M | 5.9M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | GLMD | XBIO |
|---|---|---|
| Price | $1.14 | $2.48 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 6.3M | 56.4K |
| Earning Date | 11-26-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $2,858,935.00 |
| Revenue This Year | N/A | $1.99 |
| Revenue Next Year | N/A | $20.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 13.30 |
| 52 Week Low | $0.74 | $2.20 |
| 52 Week High | $3.61 | $13.93 |
Technical Indicators
Market Signals| Indicator | GLMD | XBIO |
|---|---|---|
| Relative Strength Index (RSI) | 53.66 | 42.31 |
| Support Level | $0.81 | $2.31 |
| Resistance Level | $0.99 | $2.66 |
| Average True Range (ATR) | 0.13 | 0.21 |
| MACD | 0.03 | 0.05 |
| Stochastic Oscillator | 49.70 | 58.14 |
Price Performance
Historical ComparisonAbout GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.